Nadja C Fenn
Overview
Explore the profile of Nadja C Fenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini E, et al.
J Hematol Oncol
. 2021 Sep;
14(1):155.
PMID: 34579739
Background: Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 "don't eat me signal" is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through...
2.
Benmebarek M, Cadilha B, Herrmann M, Lesch S, Schmitt S, Stoiber S, et al.
Leukemia
. 2021 Jan;
35(8):2243-2257.
PMID: 33414484
Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia...
3.
Schmitt S, Tahk S, Lohner A, Hanel G, Maiser A, Hauke M, et al.
Front Immunol
. 2020 Dec;
11:602802.
PMID: 33281829
Conventional dendritic cell (DC) vaccine strategies, in which DCs are loaded with antigens , suffer biological issues such as impaired DC migration capacity and laborious GMP production procedures. In a...
4.
Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Wagner A, et al.
Blood
. 2018 Oct;
132(23):2484-2494.
PMID: 30275109
The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet, T-cell...
5.
Braciak T, Roskopf C, Wildenhain S, Fenn N, Schiller C, Schubert I, et al.
Oncoimmunology
. 2018 Sep;
7(9):e1472195.
PMID: 30228941
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of...
6.
Ponce L, Fenn N, Moritz N, Krupka C, Kozik J, Lauber K, et al.
Oncotarget
. 2017 Jan;
8(7):11284-11301.
PMID: 28061465
CD47, expressed on a variety of tumor cells, confers immune resistance by delivering an inhibitory "don't eat me" signal to phagocytic cells via its myeloid-specific receptor SIRPα. Recent studies have...
7.
Schiller C, Braciak T, Fenn N, Seidel U, Roskopf C, Wildenhain S, et al.
Oncotarget
. 2016 Nov;
7(50):83392-83408.
PMID: 27825135
Triplebodies are antibody-derived recombinant proteins carrying 3 antigen-binding domains in a single polypeptide chain. Triplebody SPM-1 was designed for lysis of CD19-bearing malignant B-lymphoid cells through the engagement of CD16-expressing...
8.
Roskopf C, Braciak T, Fenn N, Kobold S, Fey G, Hopfner K, et al.
Oncotarget
. 2016 Mar;
7(16):22579-89.
PMID: 26981773
Simultaneous targeting of multiple tumor-associated antigens (TAAs) in cancer immunotherapy is presumed to enhance tumor cell selectivity and to reduce immune escape.The combination of B lymphoid marker CD19 and myeloid...
9.
Chatzopoulou E, Roskopf C, Sekhavati F, Braciak T, Fenn N, Hopfner K, et al.
Analyst
. 2016 Mar;
141(7):2284-95.
PMID: 26958659
Cancer therapy via redirected lysis mediated by antibodies and antibody-derived agents relies on the availability of substantial numbers of sufficiently active immune effector cells. To monitor antitumor responses before and...